Ethnic Variability in the Plasma Exposures of OATP1B1 Substrates Such as HMG-CoA Reductase Inhibitors: A Kinetic Consideration of Its Mechanism
- 7 November 2012
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 94 (1), 37-51
- https://doi.org/10.1038/clpt.2012.221
Abstract
Because the plasma exposure levels of rosuvastatin in Asians are generally twice those in Caucasians, the starting dose for Asians in the United States is set to half of that for non‐Asians. However, the precise role of ethnicity in the clearance of rosuvastatin has not yet been clarified. This review focuses on ethnic variability in the clinical pharmacokinetics of 3‐hydroxy‐3‐methylglutaryl co‐enzyme A (HMG‐CoA) reductase inhibitors (statins) and angiotensin II receptor antagonists. The mechanisms of such variability are discussed quantitatively, with building a hypothetical model for pravastatin, and validated against other statins. Our analyses suggest that the ethnic variability in the plasma exposure of statins cannot be explained only by the difference in the allele frequencies of organic anion–transporting polypeptide (OATP)1B1 and breast cancer resistance protein (BCRP), and the intrinsic ethnic variability in the activity of OATP1B1 (the ratio of Japanese/Caucasians is 0.584) must be considered. Further work and validation with additional data will clarify the applicability of this model to other OATP1B1 substrates. Clinical Pharmacology & Therapeutics (2013); 94 1, 37–51. doi:10.1038/clpt.2012.221Keywords
This publication has 72 references indexed in Scilit:
- Use of Mechanistic Modeling to Assess Interindividual Variability and Interspecies Differences in Active Uptake in Human and Rat HepatocytesDrug Metabolism and Disposition, 2012
- Common Nonsynonymous Substitutions in SLCO1B1 Predispose to Statin Intolerance in Routinely Treated Individuals With Type 2 Diabetes: A Go-DARTS StudyCancer Cell, 2010
- Hepatic Metabolism and Transporter Gene Variants Enhance Response to Rosuvastatin in Patients With Acute Myocardial InfarctionCirculation: Cardiovascular Genetics, 2010
- Impact of OATP transporters on pharmacokineticsBritish Journal of Pharmacology, 2009
- The SLCO1B1*5Genetic Variant Is Associated With Statin-Induced Side EffectsJournal of the American College of Cardiology, 2009
- The Role of Transporters in the Pharmacokinetics of Orally Administered DrugsPharmaceutical Research, 2009
- SLCO1B1 variants and statin-induced myopathy - A genomewide studyNew England Journal of Medicine, 2008
- Ethnic or Racial Differences RevisitedClinical Pharmacokinetics, 2006
- Population Pharmacokinetics of Olmesartan Following Oral Administration of its Prodrug, Olmesartan MedoxomilClinical Pharmacokinetics, 2005
- A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerationsJournal of Pharmacokinetics and Biopharmaceutics, 1986